Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Rhea-AI Summary
Triera Biosciences (NASDAQ:ZTEK) is launching contract research organization services for custom aptamer discovery, biosensor enablement, and ML classification support on March 25, 2026.
Built on an exclusive 20-year McMaster University license, Triera offers integrated SELEX aptamer development, biosensor integration, and optional ML signal classification targeting infectious disease and oncology diagnostics across North America and Europe.
Positive
- Exclusive 20-year McMaster license for aptamer technology
- Reported sub-nanomolar binding (Kd) for selected research targets
- Catalog includes aptamers for influenza A, SARS-CoV-2, VEGF, syphilis, norovirus, C. difficile
- Asset-light, client-funded CRO model while retaining IP
- Addresses diagnostics markets cited up to USD 155B (cancer diagnostics projection)
Negative
- None.
News Market Reaction – ZTEK
In the Mar 25 session, ZTEK declined 2.75%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Litigation outcome | Positive | -1.9% | Favorable court judgment dismissing most claims tied to former CEO. |
| Mar 09 | Project engagement update | Positive | +0.5% | PDAC 2026 update on government and First Nations engagement for Albany. |
| Mar 04 | Commercial pilot program | Positive | +0.0% | Pilot evaluation with Quality Filters to test Zentek filtration media. |
| Feb 26 | Project advancement plan | Positive | +4.9% | Plan to advance Albany Graphite toward new PEA and PFS with funding focus. |
| Feb 25 | Nasdaq compliance extension | Negative | +1.2% | 180-day extension to regain compliance with $1.00 minimum bid price. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw mixed or contrary price reactions, with more divergences than alignments to headline tone.
Over the past months, Zentek has focused on litigation resolution, core-platform sharpening, and advancing Albany Graphite, ZenGUARD, and Triera. A favorable court judgment on Mar 12, 2026 was followed by a mild negative move, while government engagement and a new PEA plan for Albany on Feb 26, 2026 coincided with a 4.89% gain. Compliance extensions from Nasdaq saw modest positives. Today’s CRO-launch announcement for Triera fits the ongoing pivot toward IP-led, B2B commercialization and earlier-revenue initiatives.
Key Terms
aptamer medical
biosensor technical
machine-learning technical
vascular endothelial growth factor medical
vegf medical
clostridioides difficile medical
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Backed by an Exclusive 20-Year McMaster University License, Triera Targets High-Priority Infectious Disease and Oncology Detection Markets Across Canada, the United States, and Europe
GUELPH, ON / ACCESS Newswire / March 25, 2026 / Zentek Ltd. (TSXV:ZEN)(NASDAQ:ZTEK) ("Zentek" or the "Company") announces that its wholly-owned subsidiary, Triera Biosciences Ltd. ("Triera"), plans to begin offering contract research organization ("CRO") services for custom aptamer discovery, biosensor enablement, and machine-learning ("ML") classification support to pharmaceutical, biotechnology, and diagnostics organizations in Canada, the United States, Europe, and other markets that require high-performance molecular recognition tools but do not have in-house SELEX expertise, biosensor engineering capability, or ML classification systems to develop them.
A Differentiated Platform Built on Deep Science
Triera's aptamer discovery capabilities were developed in collaboration with Dr. Yingfu Li's research team at McMaster University, a globally recognized leader in functional nucleic acid chemistry and SELEX methodology. Triera holds an exclusive, worldwide, royalty-bearing license from McMaster University to use and practice aptamer applications developed through this collaboration for the next 20 years: a durable scientific foundation the Company believes represents a meaningful competitive position in the CRO services landscape.
What distinguishes Triera's CRO model is its integration of three capabilities within a single engagement: (i) custom aptamer discovery and optimization via SELEX, (ii) biosensor engineering and integration support, and (iii) optional ML classification systems for signal interpretation. Aptamers are chemically synthesized, enabling consistent batch-to-batch production, rapid iteration, and defined stability profiles - structural advantages over antibody-based molecular recognition tools in certain diagnostic and sensing applications.
Triera's current catalogue contains aptamers for clinically and commercially significant targets including influenza A, SARS-CoV-2, vascular endothelial growth factor (VEGF, a solid tumour biomarker), syphilis, norovirus, and Clostridioides difficile, among others under development, with binding affinity values (Kd) reported in the sub-nanomolar range for selected research targets.
Target Disease Areas - Global Burden & Addressable Market*
Target | Global Disease Burden | Diagnostic Market Size | Growth Rate |
|---|---|---|---|
Influenza A | 3-5M severe illness cases/year 290K-650K respiratory deaths/year H5N1 pandemic risk actively monitored globally | USD 1.5B (2025, rapid influenza diagnostics) USD 2.6B projected by 2033 | |
Syphilis | 8M new adult cases/year 230K deaths/year 700K congenital syphilis cases (2022) | USD 1.1B (2024, STI diagnostics) USD 2.5B+ projected by 2032 | |
VEGF (a cancer biomarker) | 18M new cases/year; 9.0M deaths; 35M+ projected by 2050 (+ | USD 109.6B (2024, cancer diagnostics) USD 155B projected by 2030 | |
Norovirus | 685M cases/year 200K deaths/year USD 60B annual global economic burden | USD 800M+ (2024, GI molecular diagnostics) No FDA-approved vaccine - active diagnostics gap | ~ (GI diagnostics) |
C. difficile | Fastest-growing diarrheal pathogen burden globally DALYs ~doubled 1990-2021 | USD 560M+ (2024, CDI diagnostics) Institutional procurement channel well-established | ~ (HAI diagnostics) |
Asset-Light CRO Model: Client Funded, IP Retained
Triera operates as an upstream molecular recognition supplier: it develops and delivers validated aptamer sequences and biosensor-ready outputs to pharmaceutical, biotechnology, and diagnostics manufacturers, while retaining ownership of all underlying intellectual property. Client engagements are structured to be funded by the client, consistent with Zentek's broader asset-light, IP-commercialization strategy.
In alignment with Zentek's strategic focus, Triera expects these planned CRO activities may help generate earlier and more predictable revenue, supporting internal development capacity and the Company's broader diagnostic and pharmaceutical product initiatives. Successful engagements may expand into follow-on programs and, where appropriate, licensing or product partnerships. Organizations interested in exploring a project can contact the Company using the information below.
Commentary
"Triera was built to commercialize a deep body of aptamer science into real-world diagnostics and therapeutics," said Mohammed (Moe) Jiwan, Chief Executive Officer of Zentek Ltd. "Our platform is grounded in one of the world's leading academic aptamer programs, protected by a 20-year exclusive license, and aligned with the most urgent diagnostic gaps in infectious disease and oncology across North America and Europe. By offering CRO services, we can help pharmaceutical and biotech teams access custom molecular recognition tools and accelerate their development timelines, while generating near-term revenue that supports Triera's long-term product roadmap."
About Triera Biosciences Ltd.
Triera holds an exclusive, worldwide, royalty-bearing license from McMaster University to use and practice aptamer applications developed through the collaboration with the Li Lab for the next 20 years. Triera and McMaster's combined expertise and capabilities in aptamer technology offer potential to reduce the cost and time required for the development of new treatments.
About Zentek
Zentek Ltd. is a Canadian intellectual property development and commercialization company advancing a portfolio of graphene-enabled and advanced material technologies across clean air, next-generation materials, and critical minerals. The Company's core platforms are Albany Graphite, ZenGUARD™, and Triera.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
*Table sources (burden; market): (1) Influenza A: World Health Organization (WHO), "The burden of influenza" (30 Mar 2024) (3-5M severe cases; 290K-650K respiratory deaths/yr); Data Bridge Market Research, "Global Rapid Influenza Diagnostics Market...Forecast to 2033" (accessed Mar 24, 2026) (USD 1.50B 2025; USD 2.72B 2033; CAGR
For further information:
Mohammed (Moe) Jiwan
Chief Executive Officer, Zentek Ltd.
T: 416-709-8876
E: mjiwan2@zentek.com
W: www.zentek.com
SOURCE: Zentek Ltd.
View the original press release on ACCESS Newswire